Program FEW

Thursday 10th of October 2024

Advisory boards & CMG board

(The first part of the workshop is for invited physicians, second part for members of CMG board only)

18.00-19.00 Advisory Board BMS

20.00-22.30 Czech Myeloma Group Board

- topic: treatment cooperation & delegation & regional centers

Dinner will be served from 19.00 to 20.00 hours after ABs

Friday 11th of October 2024

Educational Workshops

07.30 – 08.30 Sanofi Advisory board

08.30 - 09.30 Johnson&Johnson Advisory Board

09.45 – 10.30 Implementation of new immunotherapeutic data to RMG

and related projects

(TBD)

Coffee break

11.00 – 12.00 New platform of RMG – update (CMG nad IBA representatives)

Practical experience of automatic data transfer RMG – IS FN Ostrava

(J. Svatošová/R.Hájek)

12.00 – 13.00 Lunch

Pharmaco-economic Workshop (hybrid meeting)

13.00 Welcome and Introduction

R. Hájek (Ostrava)

13.05 – 13.55 Register of Monoclonal Gammopathies (RMG) of CMG

Moderator: V. Maisnar (Hradec Králové)

RMG register update summary

V. Maisnar (Hradec Králové)

Triplet based on lenalidomide - comparison of long-term prognosis J.Minařík (Olomouc)

Comparison RWE data France vs Czech Rep (Honeur project )

R. Hájek (Ostrava)

(all presentations have limit 7 min. without discussion)

13.55 – 14.10 R.Hájek (Ostrava): Toward increasing curability & reducing cost of the treatment

14.15 – 15.30 Discussion (representatives of SÚKL, Insurance companies, CHS and CMG)

Moderator: Jakub Radocha (Hradec Králové)

Topic 1

Estimated market penetration of the evaluated drug: No. of patients & budget impact

Intro: R.Hájek (Ostrava)

Topic 2

Rules for second drug asking for approval should be similar as for the first one

approved

Intro: R.Hájek (Ostrava)

Topic 3

Rules for reimbursement that do not make practical as well as common sense

(examples & discussion)

Intro: J.Minařík (Olomouc)

Topic 4

Orphan drug evaluation according §39 : relevant comparator could be challenge!

Intro: J.Radocha (Hradec Králové)

Topic 5 – practical notes about reimbursement for insurance companies

Reimbursement challenges & issues (examples & discussion)

Intro: A. Jungová (Plzeň)

(intro presentations have limit 5 min.)

Coffee break

15.45 – 16.15 Priorities for Czech Republic

Moderator: J. Straub (Praha)

New diagnostic tools in Multiple Myeloma

M.Štork (Brno)

Rational use of bispecific antibodies in Czech Republic & CAR-T availability in 2025

J.Radocha (Hradec Králové)

16.15 – 16.45 Up-date of academic clinical trials of CMG/EMN and

Moderator: L. Pour (Brno)

M. Dorociaková (CMG): EMN trials for NDMM/RRMM – update

L.Broskevičová (Ostrava): EMN biobanking project

R.Hájek (Ostrava): CMG trial – belantamab mafodotin dose optimalization trial

16.45 – 18.00 Meeting of CMG board members, CMG foundation

members and heads of regional hematology centers

Moderator: I. Mareschová and R. Hájek

Saturday 12th October 2024

8.30 – 13.00 Meeting of CMG – RMG working group